萊茵生物(002166.SZ)半年度淨利潤降8.93%至5384.04萬元
格隆匯 8 月 26日丨萊茵生物(002166.SZ)發佈2020年半年度報告，公司合併報表範圍內實現營業總收入280,652,409.37元，較上年同期增加7.23%，實現營業利潤62,433,629.86元，較上年同期減少8.12%；實現歸屬於上市公司股東的淨利潤53,840,422.69元，較上年同期減少8.93%。
報告期，公司植物提取業務的經營業績穩步增長，實現的營業收入24,522.10萬元，佔公司合併營業收入的87.38%，較上年同期增長18.66%，淨利潤較上年同期增長11.93%，主營業務增長態勢良好。公司BT項目由於接近尾聲，確認的營業收入3,319.09萬元，佔公司合併營業收入的11.83%，較上年同期減少31.81%，淨利潤較上年同期減少27.33%，對公司報告期整體業績表現造成一定影響。
報告期公司天然甜味劑相關產品的營業收入達1.57億元，佔公司植物提取業務營業收入的64.32%。2018年公司與芬美意簽訂的累計目標收入為4億美元的天然甜味劑採購合同，為公司未來幾年天然甜味劑業務的長足發展奠定了堅實的基礎。目前公司通過與芬美意的合作，已成功與全球食品飲料品牌如達能、雀巢及百事可樂等建立了合作關係。
報告期內，我們很高興的看到，國內終端消費品市場對於無糖甜味劑產品的應用掀起了一股熱潮，特別是湧現了一批以元氣森林為代表的新興國潮品牌，對零卡零糖零脂甜味劑原料的青睞，其產品也獲得了大量年輕消費者的喜愛。從公司上半年的財務數據來看，國內銷售的植物提取業務收入較上年同期大幅提升55.72%，公司長期與國外知名消費品牌合作的能力，也逐步獲得更多國內品牌的認可。公司未來將持續開拓國內市場，爭取為國內消費者提供更多高端優質的天然甜味劑產品。
為進一步提升天然甜味劑業務的競爭力，公司於今年8月籌劃了2020年非公開發行股票工作，募集資金主要用於甜葉菊專業提取工廠建設和補充流動資金，公司控股股東秦本軍先生基於對天然甜味劑市場的發展前景的信心，擬出資9.2億元全額認購本次非公開發行的股票。本次非公開發行完成後，將有利於幫助公司抓住天然甜味劑市場的發展機遇，提升業務規模和市場佔有率，持續為國內外客户提供優質的產品和服務。
2019年公司充分發揮在植物提取行業具備的技術研發優勢，抓住發展機遇，在美國印第安納州開展工業大麻提取業務，投資約4億元建設“工業大麻提取及應用工程建設項目”，本項目是公司戰略發展方向的重要業務佈局，也是“大單品”發展策略的重要延伸。項目的建成投產將為公司增加新的利潤增長點，提高公司的盈利能力和核心競爭力，為股東創造更多價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
